Dyne Therapeutics, Inc. (DYN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Waltham, MA, アメリカ. 現CEOは John G. Cox.
DYN を有する IPO日 2020-09-17, 192 名の正社員, に上場 NASDAQ Global Select, 時価総額 $3.27B.
Dyne Therapeutics, Inc. is a biotechnology company focused on developing disease-modifying therapeutics for genetically driven muscle diseases. The company leverages its proprietary FORCE platform to advance treatment programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare skeletal, cardiac, and metabolic muscle diseases. Founded in 2017 and headquartered in Waltham, Massachusetts, Dyne operates primarily in the United States market, addressing significant unmet medical needs in the muscle disease therapeutic space.
